Alfaxalone Synthesis A Cleaner Route to a Widely Used Veterinary Anaesthetic

This patent describes a process for preparing and purifying alfaxalone, a neurosteroid anaesthetic widely used in veterinary practice, starting from a crude mixture of 3-alpha and 3-beta hydroxy isomers and delivering greater than 95 percent pure 3-alpha-hydroxy-5-alpha-pregnane. The improvement lies in chemistry that resolves the two isomers efficiently enough to support manufacturing scale.

The Problem

Steroid anaesthetics act on the GABA-A receptor to produce profound, dose-controllable central nervous system depression with favourable haemodynamic properties, which is why alfaxalone has become a mainstay of small-animal induction protocols. The molecule’s pharmacology, however, depends on a precise three-dimensional configuration. The synthetic route to alfaxalone yields a mixture of the active 3-alpha hydroxy isomer and the 3-beta hydroxy diastereomer, and separating them at production scale has historically been the limiting step in commercial supply. Existing chromatography and recrystallisation processes can be expensive, low-yielding and difficult to validate against the standards expected of a GMP pharmaceutical intermediate.

What This Invention Does

The patent provides a novel process for preparing and purifying alfaxalone from a crude mixture of 3-alpha and 3-beta hydroxy-5-alpha-pregnane intermediates. The chemistry transforms the mixture so that the desired 3-alpha hydroxy steroid is recovered in greater than 95 percent purity, suitable for the drug substance specification required of the finished product. The disclosure covers the reaction conditions, the catalysts and reagents involved, and the work-up and isolation steps that bring the product to high diastereomeric purity.

By improving the resolution step, the route is intended to be more scalable and reproducible than prior published methods, supporting Zoetis’s manufacturing of Alfaxan and related products.

Key Features

• Selective recovery of the 3-alpha isomer. Chemistry tuned to separate the pharmacologically active 3-alpha hydroxy diastereomer from its 3-beta counterpart with high efficiency.
• Greater than 95 percent purity target. Output meets the level of diastereomeric purity needed for an anaesthetic drug substance.
• Scalable to manufacturing. Designed to work at production volumes typical of veterinary pharmaceutical supply, rather than purely as a bench preparation.
• Defined reaction conditions. The patent specifies the catalyst, solvent and process window, giving the claims practical scope and supporting freedom to manufacture.
• Compatible with prior alfaxalone art. The route slots into the broader steroid manufacturing landscape and protects an incremental but commercially significant step.

Who Is Behind It

The applicant is Zoetis Services LLC, a subsidiary of Zoetis Inc., the largest dedicated animal health company in the world and the maker of Alfaxan, the leading branded alfaxalone product for cats, dogs and exotic species. The named inventors are Campbell F. Scott, Andrew Jeng Shyan Lin, Louise Sally McLaren, Jessie Lauren Webber and Rane Ranashinghe, a team consistent with a process chemistry and manufacturing group rather than purely discovery. The Australian application is a divisional of AU 2025283610, itself a divisional of AU 2024227565. The Australian patent attorney is Pizzeys Patent and Trade Mark Attorneys in Brisbane.

Why It Matters

Alfaxalone is one of the most widely used induction agents in veterinary medicine in Australia, used routinely in companion-animal practice and many specialty settings. A manufacturing-route patent of this kind is the sort of asset that protects the supply chain for an existing branded product rather than a new chemical entity, and it can deter generics that depend on cost-effective access to the same purified intermediate. Securing protection in Australia, a large and growing companion-animal market, reinforces Zoetis’s competitive position in a category that is otherwise mature.

Related Concepts

• Alfaxalone – the active drug substance whose synthesis is being protected.
• Neurosteroid – the broader pharmacological class that alfaxalone belongs to.
• Diastereomer – the type of isomeric impurity the new process is engineered to suppress.
• Good manufacturing practice – the regulatory framework that drives the high-purity specification.
• Veterinary anaesthesia – the clinical context for the finished drug product.

---

AU 2026201872 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.